Compare ISPC & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ISPC | LYRA |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 5.6M |
| IPO Year | 2021 | 2020 |
| Metric | ISPC | LYRA |
|---|---|---|
| Price | $0.38 | $1.98 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 1.8M | 104.0K |
| Earning Date | 11-17-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,352,744.00 | $600,000.00 |
| Revenue This Year | $35.93 | N/A |
| Revenue Next Year | N/A | $93.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.26 | $1.63 |
| 52 Week High | $3.38 | $37.50 |
| Indicator | ISPC | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 27.52 |
| Support Level | $0.29 | $1.63 |
| Resistance Level | $0.44 | $3.94 |
| Average True Range (ATR) | 0.05 | 0.25 |
| MACD | 0.02 | -0.14 |
| Stochastic Oscillator | 67.05 | 15.37 |
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.